Israeli medical device company Pocared Diagnostics Ltd. has closed $15 million in funding. The diagnostics and pre-analytical technology manufacturer is headquartered in Rehovot and has offices in the US.
Pocared Diagnostics develops leading technology platforms that improve the ability of practitioners and hospitals to implement evidence-based medicine, while reducing lab operating costs and improving profitability. The company has raised an additional $15 million (milestone-based) in funding to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000 and SP platforms.
The POCARED P-1000 analysis platform offers direct- specimen, fully automated, reagent-free microorganism detection, identification and enumeration, in minutes, by utilizing intrinsic fluorescence optical data .The SP is the next-generation sample processor delivering cell recovery, viability and robust fractionation capabilities. These technologies will be as an aid in the diagnosis of infectious diseases.
Pocared president and CEO Jonathan Gurfinkel said, "These are exciting times for POCARED as we are closer to commercializing our first two platforms to make the POCARED revolution a reality. The funding allows us to quickly build capacity in manufacturing and to begin development of further applications for the system."
Published by Globes [online], Israel business news - www.globes-online.com - on February 17, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015